Journal of Neuroimmune Pharmacology

, Volume 4, Issue 2, pp 249–259

Modulation of Cannabinoid Receptor Activation as a Neuroprotective Strategy for EAE and Stroke

  • Ming Zhang
  • Billy R. Martin
  • Martin W. Adler
  • Raj J. Razdan
  • Weimin Kong
  • Doina Ganea
  • Ronald F. Tuma
Invited Review

Abstract

Recognition of the importance of the endocannabinoid system in both homeostasis and pathologic responses raised interest recently in the development of therapeutic agents based on this system. The CB2 receptor, a component of the endocannabinoid system, has significant influence on immune function and inflammatory responses. Inflammatory responses are major contributors to central nervous system (CNS) injury in a variety of diseases. In this report, we present evidence that activation of CB2 receptors, by selective CB2 agonists, reduces inflammatory responses that contribute to CNS injury. The studies demonstrate neuroprotective effects in experimental autoimmune encephalomyelitis, a model of multiple sclerosis, and in a murine model of cerebral ischemia/reperfusion injury. In both cases, CB2 receptor activation results in reduced white cell rolling and adhesion to cerebral microvessels, a reduction in immune cell invasion, and improved neurologic function after insult. In addition, administration of the CB1 antagonist SR141716A reduces infarct size following ischemia/reperfusion injury. Administration of both a selective CB2 agonist and a CB1 antagonist has the unique property of increasing blood flow to the brain during the occlusion period, suggesting an effect on collateral blood flow. In summary, selective CB2 receptor agonists and CB1 receptor antagonists have significant potential for neuroprotection in animal models of two devastating diseases that currently lack effective treatment options.

Keywords

CB1 CB2 endocannabinoid system neuroprotection EAE stroke 

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ming Zhang
    • 1
  • Billy R. Martin
    • 2
  • Martin W. Adler
    • 1
  • Raj J. Razdan
    • 3
  • Weimin Kong
    • 4
  • Doina Ganea
    • 4
  • Ronald F. Tuma
    • 1
  1. 1.Center for Substance Abuse ResearchTemple University School of MedicinePhiladelphiaUSA
  2. 2.Department of Pharmacology and ToxicologyVirginia Commonwealth University School of MedicineRichmondUSA
  3. 3.Organix Inc.WoburnUSA
  4. 4.Department of Microbiology and ImmunologyTemple University School of MedicinePhiladelphiaUSA

Personalised recommendations